1. Home
  2. SCSC vs LTGO Comparison

SCSC vs LTGO Comparison

Compare SCSC & LTGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ScanSource Inc.

SCSC

ScanSource Inc.

N/A

Current Price

$61.70

Market Cap

1.2B

Sector

Technology

ML Signal

N/A

LTGO

Latigo Biotherapeutics Inc. Common Stock

N/A

Current Price

$16.71

Market Cap

1.2B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
SCSC
LTGO
Founded
1992
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.2B
IPO Year
1997
2026

Fundamental Metrics

Financial Performance
Metric
SCSC
LTGO
Price
$61.70
$16.71
Analyst Decision
Hold
Strong Buy
Analyst Count
4
4
Target Price
★ $60.50
$52.25
AVG Volume (30 Days)
189.9K
★ 240.1K
Earning Date
11-05-2026
11-19-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 21.33
N/A
EPS
★ 3.64
N/A
Revenue
★ $3,846,260,000.00
N/A
Revenue This Year
$10.38
N/A
Revenue Next Year
$5.47
N/A
P/E Ratio
$15.86
★ N/A
Revenue Growth
★ 7.79
N/A
52 Week Low
$33.76
$16.19
52 Week High
$66.78
$25.93

Technical Indicators

Market Signals
Indicator
SCSC
LTGO
Relative Strength Index (RSI) 57.64 34.69
Support Level $55.67 $16.19
Resistance Level $59.23 $20.49
Average True Range (ATR) 1.32 1.68
MACD -0.01 -0.67
Stochastic Oscillator 82.56 7.32

Price Performance

Historical Comparison
SCSC
LTGO

About SCSC ScanSource Inc.

ScanSource Inc is a technology distributor uniquely positioned to address complex, converging technologies and to accelerate growth for channel sales partners across hardware, SaaS, connectivity, and cloud. The Company provides technology solutions and services from suppliers of mobility and barcode, POS, payment terminals, physical security, networking, communications, connectivity, and cloud services to channel sales partners located mainly in the United States and Brazil. It has two reportable segments based on the sales model: Specialty Technology Solutions, which generates maximum revenue and includes hardware, SaaS, and subscription services through a wholesale/resale sales model, and Intelisys & Advisory. Geographically, it derives the majority of its revenue from the United States.

About LTGO Latigo Biotherapeutics Inc. Common Stock

Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.

Share on Social Networks: